Human growth hormone fragment 176-191

HGH Fragment 176-191 in Canada

Also known as hGH 176-191 · HGH Frag 176-191 · Growth hormone fragment 176-191 · Lipolytic fragment of hGH · AOD-9604 (Tyr-hGH 177-191)

HGH Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to the C-terminal tail of human growth hormone — the short region that, in the 1990s, was found to carry the hormone's fat-metabolising activity without its effects on glucose or IGF-1. It is the same sequence that Metabolic Pharmaceuticals developed as AOD-9604 and took into human obesity trials, where it was well tolerated but did not meet its primary endpoint. Canada Peptides carries research-grade HGH Fragment 176-191 as a lyophilised vial, priced and shipped in CAD for laboratory and research use only.

Quick facts

Class: Synthetic hexadecapeptide; C-terminal fragment of human growth hormone
Structure: 16 amino acids · Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe · one disulfide bridge · ~1,815 Da
Half-life: No published human pharmacokinetic study of the injectable fragment; rodent data indicate rapid clearance
Route in research: Subcutaneous, intraperitoneal and oral in rodent studies; oral tablets in the AOD-9604 human trials
Cadence in research: Once daily in most animal protocols and in the human oral trials
Storage: Lyophilised: refrigerated, dark. Reconstituted: refrigerated, used within weeks
Status in Canada

HGH Fragment 176-191 FAQ

Is HGH Fragment 176-191 for sale in Canada?

Yes. Research-grade HGH Fragment 176-191 is available in Canada from Canada Peptides as a lyophilised vial, priced and shipped in CAD. It is supplied strictly for laboratory and research use, not for human consumption.

What is HGH Fragment 176-191?

It is a synthetic 16-amino-acid peptide matching the C-terminal tail of human growth hormone. Work at Monash University found that this region reproduces growth hormone's effects on fat metabolism in rodents without its effects on growth, glucose or IGF-1.

Is HGH Fragment 176-191 the same as AOD-9604?

At the level of sequence, yes. AOD-9604 is residues 177–191 with a tyrosine added at the N-terminus, and residue 176 of growth hormone is itself a tyrosine, so both names describe the same sixteen residues. AOD-9604 is the pharmaceutical code under which Metabolic Pharmaceuticals ran human trials.

What does the research on HGH Fragment 176-191 actually show?

Consistent rodent data for reduced fat mass and increased fat oxidation without glucose or IGF-1 effects, and human trials of oral AOD-9604 that were well tolerated but did not meet the primary weight-loss endpoint. There is no controlled human study of the injectable fragment.

What is the half-life of HGH Fragment 176-191?

Unknown in humans. No pharmacokinetic study of the injectable fragment has been published in people; rodent data indicate rapid clearance, as expected for a small peptide. Half-life figures circulated for the research material are not derived from published data.

How was HGH Fragment 176-191 dosed in studies?

Rodent studies used roughly 0.25–2 mg/kg daily by injection or gavage. Human trials of AOD-9604 used oral tablets from 1 mg to 30 mg daily for twelve weeks. There is no validated human dose, and this page does not recommend one; the material sold here is for research use only.

Does HGH Fragment 176-191 raise growth hormone or IGF-1?

No. It does not bind the growth hormone receptor with meaningful affinity and did not raise IGF-1 in rodent studies or the human trials. It is a fragment studied for direct effects on fat metabolism, not a secretagogue.

Is HGH Fragment 176-191 legal in Canada?

It is not a controlled substance in Canada, but it has no Health Canada approval for human use and no DIN. It may be sold for laboratory research, which is how it is sold here. WADA lists hGH 176-191 by name under S2, so it is prohibited for tested athletes.

HGH Fragment 176-191 in Canada

Quick facts

HGH Fragment 176-191 — for sale in Canada

What is HGH Fragment 176-191?

Evidence at a glance

Pharmacology

Identity and chemistry

Storage and stability

Research indications

Research protocols

Interactions and stacking in research

Reconstitution and handling

Side effects and safety signals

Regulatory status in Canada

Further reading

HGH Fragment 176-191 FAQ

Research references